Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciprofloxacin extended release - Assertio Therapeutics

Next Previous
Search
Drug Profile

Ciprofloxacin extended release - Assertio Therapeutics

Alternative Names: Ciprofloxacin controlled release - Assertio Therapeutics; Ciprofloxacin gastric retention; Ciprofloxacin GR; Ciprofloxacin hydrochloride extended release - Assertio Therapeutics; Ciprofloxacin hydrochloride prolonged-release tablets - Assertio Therapeutics; Proquin XR; URITENT; UTIMINX

Latest Information Update: 04 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Depomed
  • Developer Assertio Therapeutics
  • Class Anti-infectives; Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules; Urinary anti-infective agents
  • Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Urinary tract infections

Highest Development Phases

  • Market Withdrawal Urinary tract infections

Most Recent Events

  • 15 Aug 2018 Depomed is now called Assertio Therapeutics
  • 31 Oct 2010 Withdrawn for Urinary tract infections in USA (PO)
  • 24 Jul 2008 Registered for Urinary tract infections in Sweden (PO, Controlled release, 500mg, Once daily)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top